Clinical Trials

181 results for Kidney/Renal Cancer


A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features

  • Condition: Kidney Cancer
  • Intervention: Drug: gemcitabine hydrochloride, Drug: sunitinib malate
  • Study ID: NCT01164228
View Trial

A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Intervention: Device: CyberKnife
  • Study ID: NCT01890590
View Trial

Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery

  • Condition: Clear-cell Metastatic Renal Cell Carcinoma
  • Intervention: Drug: sunitinib or pazopanib, Procedure: Cytoreductive nephrectomy
  • Study ID: NCT02535351
View Trial

A Phase 3, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (msb0010718c) In Combination With Axitinib (Inlyta(Registered)) Versus Sunitinib (Sutent(Registered)) Monotherapy In The First-line Treatment Of Patients With Advanced Renal

  • Condition: Renal Cell Cancer
  • Intervention: Drug: Avelumab (MSB0010718C), Drug: Axitinib (AG-013736), Drug: Sunitinib
  • Study ID: NCT02684006
View Trial

A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE

  • Condition: Renal Cell Carcinoma
  • Intervention: Biological: Pembrolizumab, Drug: Axitinib, Drug: Sunitinib
  • Study ID: NCT02853331
View Trial

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma.

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: lenvatinib, Drug: everolimus, Drug: pembrolizumab, Drug: Sunitinib
  • Study ID: NCT02811861
View Trial

A Phase III, Open-Label, Randomized Study Of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: Atezolizumab [TECENTRIQ], Drug: Bevacizumab, Drug: Sunitinib
  • Study ID: NCT02420821
View Trial

Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)

  • Condition: Prostate Cancer, Renal Cell Carcinoma, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Advanced MET Amplified Solid Tumor
  • Intervention: Device: Mesenchymal-marker based ferrofluid (c-MET), Device: Epithelial cell adhesion molecule (EpCAM) ferrofluid
  • Study ID: NCT02080650
View Trial

Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

  • Condition: Renal Cancer
  • Intervention: Drug: 124IcG250
  • Study ID: NCT01582204
View Trial

A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma

  • Condition: Kidney Cancer
  • Intervention: Drug: Pazopanib, Drug: Temsirolimus, Behavioral: Quality of Life Assessment, Drug: Benadryl
  • Study ID: NCT01392183
View Trial

Pragmatic Study Evaluating The Impact Of A Therapy Management Platform On The Management Of Patients Suffering From Advanced/Metastatic Renal Cell Carcinoma And Receiving First Line Treatment With Sunitinib, Versus Standard Follow-up

  • Condition: Metastatic/Advanced Renal Cell Carcinoma
  • Intervention: Other: Best supportive care, Other: call center, Other: Best supportive care
  • Study ID: NCT02187042
View Trial

Developing Non-Invasive Early Therapeutic Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma

  • Condition: Metastatic Renal Cell Cancer
  • Intervention: Procedure: perfusion computed tomography
  • Study ID: NCT01926990
View Trial

Clinical Registry Describing Treatment Reality and Therapy Modality of Patients With Metastatic or Locally Advanced Renal Cell Carcinoma Requiring Therapy

  • Condition: Renal Cell Carcinoma
  • Study ID: NCT00610012
View Trial

A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: everolimus and bevacizumab
  • Study ID: NCT01399918
View Trial

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

  • Condition: Papillary Renal Cell Carcinoma
  • Intervention: Drug: INC280
  • Study ID: NCT02019693
View Trial

An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE).

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: RAD001
  • Study ID: NCT01206764
View Trial

A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma

  • Condition: Metastatic Renal Cell Cancer
  • Intervention: Drug: RX-0201, Drug: Everolimus
  • Study ID: NCT02089334
View Trial

A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

  • Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
  • Intervention: Drug: Pazopanib
  • Study ID: NCT01521715
View Trial

A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a lead-in Phase 1B Dose Escalation Portion) in Patients With Advanced or Metastatic Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Intervention: Drug: TRC105 and Axitinib
  • Study ID: NCT01806064
View Trial

A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma

  • Condition: Advanced Renal Cell Carcinoma
  • Intervention: Drug: Dalantercept and axitinib, Drug: Placebo and axitinib
  • Study ID: NCT01727336
View Trial

Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel®), Sunitinib (Sutent®), And Axitnib (Inlyta®) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl), And

  • Condition: Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
  • Intervention: Drug: Temsirolimus, Drug: Temsirolimus, Drug: Sunitinib, Drug: Sunitinib, Drug: Axitinib
  • Study ID: NCT00700258
View Trial

Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients

  • Condition: Renal Cell Cancer
  • Study ID: NCT02071719
View Trial

A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

  • Condition: ccRCC, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
  • Intervention: Drug: PART 1: PT2385 Tablets, Drug: PART 2: PT2385 Tablets in combination with nivolumab, Drug: PART 3: PT2385 Tablets in combination with cabozantinib
  • Study ID: NCT02293980
View Trial

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

  • Condition: HLRCC, Metastatic Papillary RCC
  • Intervention: Drug: Bevacizumab, Drug: Erlotinib
  • Study ID: NCT01130519
View Trial

A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Subjects With Advanced Renal Cell Carcinoma

  • Condition: Carcinoma, Renal Cell
  • Intervention: Drug: Pazopanib, Drug: MK-3475
  • Study ID: NCT02014636
View Trial

A Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma

  • Condition: Colorectal Cancers
  • Intervention: Biological: RENCA macrobeads
  • Study ID: NCT02046174
View Trial

Axitinib In Advanced / Metastatic Renal Cell Carcinoma - A Non-interventional Study Of Real World Treatment Outcomes In Patients Receiving 2nd Line Axitinib After 1st Line Sunitinib (Adonis)

  • Condition: Metastatic Renal Cell Carcinoma (mRCC)
  • Intervention: Other: observational
  • Study ID: NCT02184416
View Trial

An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma

  • Condition: Pancreatic Cancer, Colorectal Cancer
  • Intervention: Biological: Cancer macrobead placement in abdominal cavity
  • Study ID: NCT01053013
View Trial

A Phase I Open-Label, Non-Randomized, Dose-Escalation Study of rSIFN-co in Subjects With Advanced Solid Tumors and With an Expansion Cohort at Recommended Dose (RD) in Subjects With Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma, Melanoma, Hepat

  • Condition: Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Carcinoma, Hepatocellular, Colon Cancer
  • Intervention: Drug: rSIFN-co
  • Study ID: NCT02387307
View Trial

Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety and PK/PD

  • Condition: Hepatocellular Carcinoma, Renal Cell Carcinoma, Melanoma, Prostate Adenocarcinoma
  • Intervention: Biological: PEG-BCT-100
  • Study ID: NCT02285101
View Trial

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

  • Condition: Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Mesothelioma, Fumarate Hydratase (FH)-Deficient Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydro
  • Intervention: Drug: CB-839, Drug: Pac-CB, Drug: CBE, Drug: CB-Erl, Drug: CBD, Drug: CB-Cabo
  • Study ID: NCT02071862
View Trial

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

  • Condition: Advanced Cancer
  • Intervention: Drug: MGCD516
  • Study ID: NCT02219711
View Trial

A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies

  • Condition: Renal Cell Carcinoma, Mantle-Cell Lymphoma, Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3
  • Intervention: Drug: SGN-CD70A
  • Study ID: NCT02216890
View Trial

Phase II Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer (CRAD001CUS242T)

  • Condition: Ovarian Cancer, Endometrial Cancer
  • Intervention: Drug: everolimus and letrozole
  • Study ID: NCT02188550
View Trial

Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses

  • Condition: Carcinoma, Renal Cell
  • Intervention: Device: Sonatherm 600i ablation system
  • Study ID: NCT02248389
View Trial

A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

  • Condition: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
  • Intervention: Drug: Gemcitabine, Drug: pazopanib
  • Study ID: NCT01610206
View Trial

A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity

  • Condition: Lung Cancer
  • Intervention: Drug: Sunitinib
  • Study ID: NCT01829217
View Trial

Phase I Study of Temsirolimus and Cetuximab in Adults Patients With Advanced or Metastatic Solid Tumors

  • Condition: Patients With Advanced or Metastatic Solid Tumors
  • Intervention: Drug: Cetuximab, Drug: Temsirolimus
  • Study ID: NCT02215720
View Trial

Improving the Tolerability of the Oral Targeted Anticancer Drug Pazopanib by Food Intake (DIET)

  • Condition: Cancer
  • Intervention: Drug: pazopanib, Other: continental breakfast
  • Study ID: NCT02138526
View Trial

Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE")

  • Condition: Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveo
  • Intervention: Drug: Crizotinib (PF-02341066)
  • Study ID: NCT01524926
View Trial

Phase II Randomized Study of Docetaxel With or Without Low-dose, Short Course Sunitinib in the Treatment of Advanced Solid Tumors

  • Condition: Solid Tumors, Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer, Gastric Cancer
  • Intervention: Drug: Docetaxel, Drug: Sunitinib
  • Study ID: NCT01803503
View Trial

A Phase 1 Study of Subcutaneous Recombinant Human hetIL-15 (IL15/sIL-15Ra) in Adults With Metastatic Cancers

  • Condition: Skin Melanoma, Renal Cell Cancer, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
  • Intervention: Drug: hetIL-15
  • Study ID: NCT02452268
View Trial

Clinical Study of Chimeric EGFR Antigen Receptor-modified T Cells in Chemotherapy Refractory Advanced Solid Tumors

  • Condition: Advanced EGFR-positive Solid Tumors
  • Intervention: Biological: CART-EGFR
  • Study ID: NCT01869166
View Trial

Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

  • Condition: Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
  • Intervention: Drug: AZD6244, Drug: MK-2206, Drug: Lapatinib, Drug: Erlotinib, Drug: Sunitinib, Procedure: Molecular Profiling
  • Study ID: NCT01306045
View Trial

A Phase 1b, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Crizotinib (Pf-02341066) In Patients With Advanced Solid Tumors

  • Condition: Advanced Solid Tumors
  • Intervention: Drug: axitinib, Drug: crizotinib, Drug: axitinib, Drug: crizotinib, Drug: axitinib, Drug: crizotinib
  • Study ID: NCT01999972
View Trial

Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial

  • Condition: Hepatopulmonary Syndrome
  • Intervention: Drug: Sorafenib, Drug: Placebo
  • Study ID: NCT02021929
View Trial

A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

  • Condition: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma
  • Intervention: Drug: MEDI4736, Drug: Tremelimumab
  • Study ID: NCT01975831
View Trial

A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma

  • Condition: Melanoma
  • Intervention: Drug: Paclitaxel, Drug: Carboplatin, Drug: Bevacizumab
  • Study ID: NCT02023710
View Trial

A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

  • Condition: Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma, Colorectal Cancer (CRC), Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)
  • Intervention: Drug: Combination of varlilumab and nivolumab
  • Study ID: NCT02335918
View Trial

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers

  • Condition: Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Pancreatic Ducta
  • Intervention: Drug: IMMU-132
  • Study ID: NCT01631552
View Trial
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe